Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches-Reference-Cited by-同舟云学术

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

Published:2016-04-29 Issue:5 Volume:17 Page:642
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Preuner Sandra,Barna Agnes,Frommlet Florian,Czurda Stefan,Konstantin Byrgazov,Alikian Mary,Machova Polakova Katerina,Sacha Tomasz,Richter Johan,Lion Thomas,Gabriel Christian

Funder

Austrian Science Fund (FWF)

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/17/5/642/pdf

Reference31 articles.

1. Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

2. Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia;Radich;J. Natl. Compr. Cancer Netw. JNCCN,2013

3. Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression

4. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

5. BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort;Scientific Reports;2024-07-08

2. A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-04

3. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper;Journal of Hematology & Oncology;2019-12

4. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms;Hematological Oncology;2018-08-03

5. Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq;Karbala International Journal of Modern Science;2017-12